FSI965 is a next-generation basal insulin.
PYY 1875 is an appetite regulating hormone and is tested alone and in combination with semaglutide.
Combination of amylin (AM833) and semaglutide.
Human GDF15, is a stress-induced cytokine with multiple effects, one being appetite regulation leading to weight loss.
Mim8 is a next-generation factor VIII mimetic bi-specific antibody for subcutaneous prophylaxis treatment of haemophilia A regardless of inhibitor status.
The once-weekly combination of once-weekly insulin LAI287 and once-weekly injectable GLP-1 semaglutide.
EPI01 is an oral combination product for treatment of sickle cell disease.
Subcutaneous version of PCSK9i intended to treat people with hypercholesterolaemia.
A long-acting basal insulin analogue intended for once weekly dosing.
A beta-cell preservation treatment intended for people newly diagnosed with type 1 diabetes.
A long-acting amylin analogue intended as treatment for obesity.
A long-acting GLP-1 analogue intended as once-daily treatment for non-alcoholic fatty liver disease (NASH).
A long-acting GLP-1 analogue intended as a once-weekly treatment for obesity.
A monoclonal antibody against Tissue Factor Pathway Inhibitor (TFPI) intended for bleeding prevention after subcutaneous administration.
A long-acting human growth hormone intended to offer once-weekly injections.